Comparative Pharmacology
Head-to-head clinical analysis: BUTALBITAL AND ACETAMINOPHEN versus BUTALBITAL ACETAMINOPHEN AND CAFFEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALBITAL AND ACETAMINOPHEN versus BUTALBITAL ACETAMINOPHEN AND CAFFEINE.
BUTALBITAL AND ACETAMINOPHEN vs BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing pain and fever.
Butalbital is a barbiturate that acts as a nonselective central nervous system depressant, enhancing GABAergic transmission by binding to the GABA-A receptor and increasing chloride influx, leading to sedation and anxiolysis. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and providing analgesic and antipyretic effects. Caffeine is a methylxanthine that antagonizes adenosine receptors, promoting vasoconstriction and enhancing analgesic efficacy.
Tension headacheMigraine headache
Relief of tension-type headacheRelief of migraine headache (various formulations)
1-2 capsules (50 mg butalbital/300 mg acetaminophen per capsule) orally every 4 hours as needed, not to exceed 6 capsules per day.
1-2 capsules (50mg butalbital, 300mg acetaminophen, 40mg caffeine) orally every 4 hours as needed, not to exceed 6 doses per day.
None Documented
None Documented
Acetaminophen: 2-3 hours (adults), prolonged in hepatic impairment. Butalbital: 35-50 hours (terminal), indicating potential accumulation with repeated dosing.
Butalbital: 35-50 hours (long-acting barbiturate, risk of accumulation with repeated dosing). Acetaminophen: 2-4 hours (normal hepatic function). Caffeine: 3-7 hours (metabolized by CYP1A2).
Butalbital: hepatic via CYP2C19 and other CYP enzymes. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A6), sulfation, and CYP2E1 (minor pathway).
Butalbital: primarily hepatic via hydroxylation (CYP2C19, CYP2C9, CYP3A4). Acetaminophen: hepatic via conjugation (glucuronidation, sulfation) and minor oxidation via CYP2E1. Caffeine: hepatic via CYP1A2, with N-demethylation as primary pathway.
Acetaminophen: renal excretion of metabolites (glucuronide ~55%, sulfate ~30%, cysteine ~3%, unchanged ~4%). Butalbital: renal excretion of metabolites (unchanged <3%, 5-15% as hydroxylated metabolites). Total renal elimination >90% combined; biliary/fecal <10%.
Butalbital: ~90% renal as unchanged drug and metabolites; Acetaminophen: ~85% renal as sulfate and glucuronide conjugates; Caffeine: ~1% renal unchanged, primarily hepatic metabolism. Biliary/fecal minimal (<5%).
Acetaminophen: 10-25% (albumin). Butalbital: 20-30% (albumin).
Butalbital: 20-30% (albumin). Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin).
Acetaminophen: 0.9-1.5 L/kg (distributes into most body fluids). Butalbital: 0.5-1.0 L/kg (moderate distribution).
Butalbital: 0.8-1.0 L/kg (distributes widely, including CNS). Acetaminophen: 0.9-1.0 L/kg (body water). Caffeine: 0.6-0.8 L/kg (rapid distribution).
Oral: Acetaminophen ~88%, Butalbital ~100% (assuming no first-pass).
Oral: Butalbital ~100%; Acetaminophen ~80-90%; Caffeine ~100% (rapid and complete absorption).
GFR 30-89 mL/min: No adjustment. GFR 10-29 mL/min: Avoid or extend dosing interval to every 6-8 hours. GFR <10 mL/min: Avoid use.
GFR 30-50 mL/min: Use with caution, increase dosing interval to every 6-8 hours. GFR <30 mL/min: Avoid or extend interval to every 12 hours due to acetaminophen accumulation.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or extend interval. Child-Pugh C: Avoid use.
Child-Pugh Class B (moderate impairment): Reduce dose by 50% and extend interval to every 6-8 hours. Child-Pugh Class C (severe impairment): Contraindicated due to butalbital and acetaminophen metabolism.
Children ≥12 years: 1 capsule (50 mg butalbital/300 mg acetaminophen) orally every 4 hours as needed, not to exceed 6 capsules per day. Children <12 years: Not recommended.
Children ≥12 years: Same as adult. Children <12 years: Not recommended due to butalbital risks. If used, weight-based: butalbital 1.0-1.5 mg/kg/dose, max 50 mg; acetaminophen 10-15 mg/kg/dose, max 300 mg; caffeine 1-2 mg/kg/dose, max 40 mg; orally every 4-6 hours as needed.
Start with 1 capsule orally every 4 hours as needed, not to exceed 6 capsules per day. Caution due to increased sensitivity to butalbital (sedation, confusion) and acetaminophen hepatotoxicity. Monitor renal and hepatic function.
Initiate at lowest effective dose (e.g., 1 capsule every 6 hours) due to increased sensitivity to butalbital (sedation, confusion) and acetaminophen hepatotoxicity risk. Monitor renal and hepatic function.
None
Butalbital can be habit-forming and may produce drug dependence (barbiturate dependence). Abrupt discontinuation may precipitate withdrawal symptoms including seizures, hallucinations, and death. Concomitant use with opioids, alcohol, or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.
["Hepatotoxicity with acetaminophen overdose","Risk of barbiturate dependence and withdrawal","CNS depression with alcohol or other depressants","Acetaminophen may cause severe skin reactions (SJS, TEN, AGEP)"]
Hepatotoxicity risk (acetaminophen toxicity) with dose >4000 mg/day or in patients with liver disease. Risk of respiratory depression with CNS depressant co-administration. Development of tolerance, dependence, and withdrawal upon abrupt discontinuation. Use with caution in elderly, debilitated patients, and those with renal impairment. Avoid chronic use (>3 months) for headache.
["Hypersensitivity to butalbital, acetaminophen, or any component","Porphyria","Severe hepatic impairment"]
Hypersensitivity to any component. Severe hepatic impairment (Child-Pugh C) or active liver disease. Acute intermittent porphyria. Severe respiratory depression or untreated sleep apnea. Concomitant use with MAO inhibitors or within 14 days of discontinuation. Butalbital contraindicated in patients with known barbiturate sensitivity or dependence.
Data Pending Review
Data Pending Review
Avoid excessive consumption of alcohol-containing foods or beverages due to risk of hepatotoxicity and CNS depression. No significant food interactions.
Avoid alcohol-containing foods or beverages (increases hepatotoxicity and CNS depression). Limit caffeine-containing products (coffee, tea, cola, energy drinks) as additive effect may cause jitteriness, tachycardia, or insomnia. Grapefruit juice may inhibit CYP1A2 and increase butalbital and caffeine levels; avoid concurrent intake.
Pregnancy Category C. First trimester: butalbital (barbiturate) may be associated with oral clefts and neural tube defects; acetaminophen is generally considered low risk but high doses may be associated with adverse outcomes. Second and third trimesters: butalbital may cause neonatal withdrawal, sedation, and respiratory depression; acetaminophen is considered safe at therapeutic doses. Chronic use of butalbital in third trimester may lead to neonatal dependence.
First trimester: Acetaminophen and caffeine are generally considered low risk; butalbital is a barbiturate and may be associated with a small increased risk of oral clefts. Second and third trimester: Chronic high-dose butalbital may cause fetal dependence and neonatal withdrawal syndrome; acetaminophen and caffeine are considered safe at therapeutic doses.
Butalbital and acetaminophen are excreted into breast milk. Acetaminophen M/P ratio approximately 1.0; butalbital M/P ratio unknown but barbiturates pass into milk. At maternal therapeutic doses, effects on infant are unlikely; however, high doses of butalbital may cause sedation or poor feeding. Caution is advised; monitor infant for drowsiness.
Acetaminophen and caffeine are excreted into breast milk in low amounts; butalbital is excreted in small quantities. M/P ratio not established. Use with caution; monitor infant for sedation and poor feeding.
No specific dosing adjustments recommended; use lowest effective dose for shortest duration. Pregnancy increases clearance of acetaminophen but not considered clinically significant. Butalbital pharmacokinetics unchanged; avoid chronic use due to risk of dependence and withdrawal.
No dose adjustment required for acetaminophen and caffeine; butalbital dose may need reduction due to increased clearance in pregnancy, but specific data lacking; use lowest effective dose for shortest duration.
Category C
Category C
Butalbital is a barbiturate that potentiates acetaminophen's analgesic effect; combination carries risk of barbiturate dependence and withdrawal. Maximum adult acetaminophen dose is 4 g/day; avoid in severe hepatic impairment or active liver disease. Monitor for respiratory depression, especially with alcohol or other CNS depressants. Abrupt discontinuation after prolonged use may cause withdrawal symptoms. Not recommended for children under 12.
Butalbital is a barbiturate with high abuse potential; limit prescribing to acute tension-type headache and monitor for overuse. Acetaminophen hepatotoxicity risk increases with alcohol use or pre-existing liver disease; total daily dose should not exceed 4 g (3 g in frail patients). Caffeine can exacerbate anxiety or insomnia; avoid in patients with cardiovascular conditions. Use with caution in renal impairment (butalbital accumulation) and in patients with porphyria. Pregnancy category C; avoid in breastfeeding (butalbital sedation, caffeine irritability).
Take exactly as prescribed; do not exceed 6 tablets per day.Avoid alcohol and other sedatives; may cause dizziness or drowsiness.Do not use with other acetaminophen-containing products to avoid liver damage.Do not stop suddenly if taken for more than 5 days; withdrawal possible.May impair ability to drive or operate machinery.Contact provider if signs of liver injury: yellow skin/eyes, dark urine, abdominal pain.Keep out of reach of children; overdose can be fatal.
Take exactly as prescribed; do not exceed 6 tablets per day due to acetaminophen liver toxicity risk.Avoid alcohol while taking this medication; can increase liver damage and sedation.This medication may cause drowsiness; do not drive or operate heavy machinery until you know how it affects you.Do not take other acetaminophen-containing products to avoid overdose.Contact your doctor if you experience severe stomach pain, yellowing of skin or eyes, or signs of an allergic reaction.Caffeine content may cause nervousness, trouble sleeping, or rapid heartbeat.Report any history of substance abuse or dependence to your healthcare provider.Store at room temperature away from moisture and heat; keep out of reach of children.